MYD88 L265P augments proximal B-cell receptor signaling in large B-cell lymphomas via an interaction with DOCK8

2.

Chapuy

B

,

Stewart

C

,

Dunford

AJ

, et al.

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

.

Nat Med

.

2018

;

24

(

5

):

679

-

690

.

3.

Schmitz

R

,

Wright

GW

,

Huang

DW

, et al.

Genetics and pathogenesis of diffuse large b-cell lymphoma

.

N Engl J Med

.

2018

;

378

(

15

):

1396

-

1407

.

4.

Wright

GW

,

Huang

DW

,

Phelan

JD

, et al.

A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications

.

Cancer Cell

.

2020

;

37

(

4

):

551

-

568.e14

.

5.

Braggio

E

,

Van Wier

S

,

Ojha

J

, et al.

Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas

.

Clin Cancer Res

.

2015

;

21

(

17

):

3986

-

3994

.

6.

Chapuy

B

,

Roemer

MG

,

Stewart

C

, et al.

Targetable genetic features of primary testicular and primary central nervous system lymphomas

.

Blood

.

2016

;

127

(

7

):

869

-

881

.

7.

Kraan

W

,

van Keimpema

M

,

Horlings

HM

, et al.

High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma

.

Leukemia

.

2014

;

28

(

3

):

719

-

720

.

8.

Oishi

N

,

Kondo

T

,

Nakazawa

T

, et al.

High prevalence of the MYD88 mutation in testicular lymphoma: immunohistochemical and genetic analyses

.

Pathol Int

.

2015

;

65

(

10

):

528

-

535

.

9.

Vater

I

,

Montesinos-Rongen

M

,

Schlesner

M

, et al.

The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing

.

Leukemia

.

2015

;

29

(

3

):

677

-

685

.

10.

Radke

J

,

Ishaque

N

,

Koll

R

, et al.

The genomic and transcriptional landscape of primary central nervous system lymphoma

.

Nat Commun

.

2022

;

13

(

1

):

2558

.

11.

Reth

M

,

Wienands

J

.

Initiation and processing of signals from the B cell antigen receptor

.

Annu Rev Immunol

.

1997

;

15

(

1

):

453

-

479

.

12.

Cambier

JC

,

Pleiman

CM

,

Clark

MR

.

Signal transduction by the B cell antigen receptor and its coreceptors

.

Annu Rev Immunol

.

1994

;

12

:

457

-

486

.

13.

Davis

RE

,

Ngo

VN

,

Lenz

G

, et al.

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

.

Nature

.

2010

;

463

(

7277

):

88

-

92

.

14.

Gazumyan

A

,

Reichlin

A

,

Nussenzweig

MC

.

Ig beta tyrosine residues contribute to the control of B cell receptor signaling by regulating receptor internalization

.

J Exp Med

.

2006

;

203

(

7

):

1785

-

1794

.

15.

Akira

S

,

Takeda

K

.

Toll-like receptor signalling

.

Nat Rev Immunol

.

2004

;

4

(

7

):

499

-

511

.

16.

Vyncke

L

,

Bovijn

C

,

Pauwels

E

, et al.

Reconstructing the TIR Side of the myddosome: a paradigm for TIR-TIR interactions

.

Structure

.

2016

;

24

(

3

):

437

-

447

.

17.

Ngo

VN

,

Young

RM

,

Schmitz

R

, et al.

Oncogenically active MYD88 mutations in human lymphoma

.

Nature

.

2011

;

470

(

7332

):

115

-

119

.

18.

Avbelj

M

,

Wolz

OO

,

Fekonja

O

, et al.

Activation of lymphoma-associated MyD88 mutations via allostery-induced TIR-domain oligomerization

.

Blood

.

2014

;

124

(

26

):

3896

-

3904

.

19.

de Groen

RAL

,

Schrader

AMR

,

Kersten

MJ

,

Pals

ST

,

Vermaat

JSP

.

MYD88 in the driver's seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications

.

Haematologica

.

2019

;

104

(

12

):

2337

-

2348

.

20.

Kawai

T

,

Akira

S

.

Signaling to NF-kappaB by toll-like receptors

.

Trends Mol Med

.

2007

;

13

(

11

):

460

-

469

.

21.

Knittel

G

,

Liedgens

P

,

Korovkina

D

, et al.

B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice

.

Blood

.

2016

;

127

(

22

):

2732

-

2741

.

22.

Sewastianik

T

,

Guerrera

ML

,

Adler

K

, et al.

Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells

.

Blood Adv

.

2019

;

3

(

21

):

3360

-

3374

.

23.

Pindzola

GM

,

Razzaghi

R

,

Tavory

RN

, et al.

Aberrant expansion of spontaneous splenic germinal centers induced by hallmark genetic lesions of aggressive lymphoma

.

Blood

.

2022

;

140

(

10

):

1119

-

1131

.

24.

Flumann

R

,

Rehkamper

T

,

Nieper

P

, et al.

An autochthonous mouse model of Myd88- and BCL2-driven diffuse large B-cell lymphoma reveals actionable molecular vulnerabilities

.

Blood Cancer Discov

.

2021

;

2

(

1

):

70

-

91

.

25.

Wang

JQ

,

Jeelall

YS

,

Humburg

P

, et al.

Synergistic cooperation and crosstalk between MYD88(L265P) and mutations that dysregulate CD79B and surface IgM

.

J Exp Med

.

2017

;

214

(

9

):

2759

-

2776

.

26.

Chaturvedi

A

,

Dorward

D

,

Pierce

SK

.

The B cell receptor governs the subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-containing antigens

.

Immunity

.

2008

;

28

(

6

):

799

-

809

.

27.

Monroe

JG

,

Keir

ME

.

Bridging toll-like- and B cell-receptor signaling: meet me at the autophagosome

.

Immunity

.

2008

;

28

(

6

):

729

-

731

.

28.

Phelan

JD

,

Young

RM

,

Webster

DE

, et al.

A multiprotein supercomplex controlling oncogenic signalling in lymphoma

.

Nature

.

2018

;

560

(

7718

):

387

-

391

.

29.

Jabara

HH

,

McDonald

DR

,

Janssen

E

, et al.

DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activation

.

Nat Immunol

.

2012

;

13

(

6

):

612

-

620

.

30.

Randall

KL

,

Lambe

T

,

Johnson

AL

, et al.

Dock8 mutations cripple B cell immunological synapses, germinal centers and long-lived antibody production

.

Nat Immunol

.

2009

;

10

(

12

):

1283

-

1291

.

31.

Kearney

CJ

,

Randall

KL

,

Oliaro

J

.

DOCK8 regulates signal transduction events to control immunity

.

Cell Mol Immunol

.

2017

;

14

(

5

):

406

-

411

.

32.

Zhang

Q

,

Davis

JC

,

Lamborn

IT

, et al.

Combined immunodeficiency associated with DOCK8 mutations

.

N Engl J Med

.

2009

;

361

(

21

):

2046

-

2055

.

33.

Engelhardt

KR

,

McGhee

S

,

Winkler

S

, et al.

Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome

.

J Allergy Clin Immunol

.

2009

;

124

(

6

):

1289

-

1302.e4

.

34.

Biggs

CM

,

Keles

S

,

Chatila

TA

.

DOCK8 deficiency: insights into pathophysiology, clinical features and management

.

Clin Immunol

.

2017

;

181

(

1

):

75

-

82

.

35.

Cote

JF

,

Vuori

K

.

GEF what? Dock180 and related proteins help Rac to polarize cells in new ways

.

Trends Cell Biol

.

2007

;

17

(

8

):

383

-

393

.

36.

Werner

M

,

Jumaa

H

.

DOCKing innate to adaptive signaling for persistent antibody production

.

Nat Immunol

.

2012

;

13

(

6

):

525

-

526

.

37.

Sun

X

,

Wang

J

,

Qin

T

, et al.

Dock8 regulates BCR signaling and activation of memory B cells via WASP and CD19

.

Blood Adv

.

2018

;

2

(

4

):

401

-

413

.

38.

Bonnette

PC

,

Robinson

BS

,

Silva

JC

, et al.

Phosphoproteomic characterization of PYK2 signaling pathways involved in osteogenesis

.

J Proteomics

.

2010

;

73

(

7

):

1306

-

1320

.

39.

Wright

KT

,

Weirather

JL

,

Jiang

S

, et al.

Diffuse large B-cell lymphomas have spatially defined, tumor immune microenvironments revealed by high-parameter imaging

.

Blood Adv

.

2023

;

7

(

16

):

4633

-

4646

.

40.

Yang

G

,

Buhrlage

SJ

,

Tan

L

, et al.

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib

.

Blood

.

2016

;

127

(

25

):

3237

-

3252

.

41.

Chapuy

B

,

McKeown

MR

,

Lin

CY

, et al.

Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma

.

Cancer Cell

.

2013

;

24

(

6

):

777

-

790

.

42.

Hegazy

M

,

Cohen-Barak

E

,

Koetsier

JL

, et al.

Proximity ligation assay for detecting protein-protein interactions and protein modifications in cells and tissues in situ

.

Curr Protoc Cell Biol

.

2020

;

89

(

1

):

e115

.

43.

Chen

L

,

Monti

S

,

Juszczynski

P

, et al.

SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas

.

Cancer Cell

.

2013

;

23

(

6

):

826

-

838

.

44.

Bojarczuk

K

,

Wienand

K

,

Ryan

JA

, et al.

Targeted inhibition of PI3Kalpha/delta is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL

.

Blood

.

2019

;

133

(

1

):

70

-

80

.

45.

Rawlings

DJ

,

Schwartz

MA

,

Jackson

SW

,

Meyer-Bahlburg

A

.

Integration of B cell responses through toll-like receptors and antigen receptors

.

Nat Rev Immunol

.

2012

;

12

(

4

):

282

-

294

.

46.

Suthers

AN

,

Sarantopoulos

S

.

TLR7/TLR9- and B cell receptor-signaling crosstalk: promotion of potentially dangerous B cells

.

Front Immunol

.

2017

;

8

:

775

.

47.

Pone

EJ

,

Zhang

J

,

Mai

T

, et al.

BCR-signalling synergizes with TLR-signalling for induction of AID and immunoglobulin class-switching through the non-canonical NF-kappaB pathway

.

Nat Commun

.

2012

;

3

:

767

.

48.

Munshi

M

,

Liu

X

,

Chen

JG

, et al.

SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas

.

Blood Cancer J

.

2020

;

10

(

1

):

12

.

49.

Lacy

SE

,

Barrans

SL

,

Beer

PA

, et al.

Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report

.

Blood

.

2020

;

135

(

20

):

1759

-

1771

.

50.

Wilson

WH

,

Wright

GW

,

Huang

DW

, et al.

Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL

.

Cancer Cell

.

2021

;

39

(

12

):

1643

-

1653.e3

.

51.

Shen

J

,

Liu

J

.

Bruton's tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: a mini-review

.

Front Oncol

.

2022

;

12

:

1034668

.

52.

Zhang

J

,

Fu

L

,

Shen

B

, et al.

Assessing IRAK4 functions in ABC DLBCL by IRAK4 kinase inhibition and protein degradation

.

Cell Chem Biol

.

2020

;

27

(

12

):

1500

-

1509.e13

.

53.

Randall

KL

,

Chan

SS

,

Ma

CS

, et al.

DOCK8 deficiency impairs CD8 T cell survival and function in humans and mice

.

J Exp Med

.

2011

;

208

(

11

):

2305

-

2320

.

54.

Lambe

T

,

Crawford

G

,

Johnson

AL

, et al.

DOCK8 is essential for T-cell survival and the maintenance of CD8+ T-cell memory

.

Eur J Immunol

.

2011

;

41

(

12

):

3423

-

3435

.

55.

Tangye

SG

,

Pillay

B

,

Randall

KL

, et al.

Dedicator of cytokinesis 8-deficient CD4(+) T cells are biased to a T(H)2 effector fate at the expense of T(H)1 and T(H)17 cells

.

J Allergy Clin Immunol

.

2017

;

139

(

3

):

933

-

949

.

56.

Singh

AK

,

Eken

A

,

Hagin

D

, et al.

DOCK8 regulates fitness and function of regulatory T cells through modulation of IL-2 signaling

.

JCI Insight

.

2017

;

2

(

19

):

e94275

.

57.

Randall

KL

,

Law

HD

,

Ziolkowski

AF

,

Wirasinha

RC

,

Goodnow

CC

,

Daley

SR

.

DOCK8 deficiency diminishes thymic T-regulatory cell development but not thymic deletion

.

Clin Transl Immunology

.

2021

;

10

(

1

):

e1236

.